Ivo Abraham, PhD

Ivo Abraham is a professor in the Department of Pharmacy Practice, with joint appointments in the Department of Family and Community Medicine (College of Medicine – Tucson) and the Clinical Translational Sciences graduate program (College of Health Sciences). He has also served on the faculty of Case Western Reserve University (Cleveland, OH), University of Virginia (Charlottesville, VA), and (part-time) KU Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, FL), Rijksuniversiteit Groningen (Groningen, The Netherlands), New York University (New York, NY), University of Pennsylvania (Philadelphia, PA) Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan), and Hyogo University (Akashi, Japan). He has lectured, consulted, and conducted research throughout the Americas, Europe, Asia, Australasia, and Africa.

A nurse by profession and a translational outcomes, effectiveness, and economics researcher by trade, his research has been funded since 1984 by public funding agencies, foundations, and corporations. He coordinates the Senza Nome (Italian, “without a name”) research group, which, on the outcomes and effectiveness side, studies how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes; and how practicing in accordance with evidence-based guidelines is associated with patient outcomes. On the economics side, and focusing mainly on pharmacotherapeutics but also models of care, his group tries to reconcile four questions: what is the clinical effect? how much does it cost? is it worth it? and, can we afford it? His translational research is focused on T2 (patients), T3 (practice), and T4 (communities), the latter also including the economic aspects.

He has (co-)authored 520+ articles and 80+ chapters, and has (co-)edited 50+ books, monographs, and journal issues. Having been a member of several editorial boards, he currently serves as the Quantitative Methods Editor of JAMA Dermatology and as Editor-in-Chief of the Journal of Medical Economics.

In the US, he has served as chartered or ad hoc study section member for the NIH, NIMH, AHRQ, VA, and NSF since 1985. He has served as an expert adviser to the Innovative Medicines and Innovative Health Initiatives, a joint 7.4 billion euro undertaking of the European Union and the industry to stimulate research and innovation in human therapeutics, vaccines, as well as diagnostics and other technologies, from their inception in 2008. He has also served as expert to various public and private funding agencies in European, Asian, and North American countries.

His educational and scientific honors and awards include several named lectureships in the US and abroad; and an invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008).